Natural variants of the Sabin type 1 vaccine strain of poliovirus and correlation with a poliovirus neutralization site.
Independent substitution mutations have been detected in capsid polypeptide VP1 of the type 1 oral poliovirus vaccine isolated from normal infant vaccine recipients. These mutations map at amino acid residues 142 and 147 of VP1, a region only minimally hydrophilic. A synthetic peptide, corresponding to residues 141 to 147 of VP1 was synthesized, conjugated to a carrier polypeptide of bovine serum albumin. The conjugate was found to elicit a weak poliovirus neutralizing antibody response. It was also capable of priming the immune system for the production of IgG-type antibodies able to neutralize greater than 99.999% of infectious type 1 virus. It is suggested that region 141 to 147 of VP1 may be involved in neutralization of the virus and that the mutants may have accumulated by antibody selection.
D000936:Antigen-Antibody Complex; D001483:Base Sequence; D002213:Capsid / Q000235:genetics*; D003062:Codon; D014644:Genetic Variation; D006801:Humans; D007106:Immune Sera; D007223:Infant; D017955:Poliovirus / Q000235:genetics* / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000276:immunology*
D000936:Antigen-Antibody Complex; D003062:Codon; D007106:Immune Sera; D011055:Poliovirus Vaccine, Oral